breast-cancer-2016_keynote

2 / 6

Volume 8, Issue 8(Suppl) J Cancer Sci Ther
ISSN: 1948-5956 JCST, an open access journal Breast Cancer Congress 2016
September 19-21, 2016
Page 22
Notes:
conferenceseries.com
Breast Cancer September 19-21, 2016 Phoenix, USA
2nd World Congress on
Shahla Masood, J Cancer Sci Ther 2016, 8:8(Suppl)
Why the term of low-grade ductal carcinoma in situ should be abandoned: minimizing over diagnosis and
overtreatment
During the last several years, increased public awareness, advances in breast imaging and enhanced screening programs
have led to early breast cancer detection and attention to cancer prevention. The numbers of image-detected biopsies
have increased and pathologists are expected to provide more information with smaller tissue samples. These biopsies have
resulted in detection of increasing numbers of high-risk proliferative breast disease and in situ cancers. The general hypothesis
is that some forms of breast cancers may arise from established forms of ductal carcinoma in situ (DCIS) and atypical ductal
hyperplasia (ADH) and possibly from more common forms of ductal hyperplasia. However, this is an oversimplification of
a very complex process, given the fact that the majority of breast cancers appears to arise de-novo or from a yet unknown
precursor lesion. Currently, ADH and DCIS are considered as morphologic risk factors and precursor lesions for breast cancer.
However, morphologic distinction between these two entities has remained a real issue that continues to lead to over-diagnosis
and overtreatment. Aside from morphologic similarities between ADH and low grade DCIS, biomarker studies and molecular
genetic testing’s have shown that morphologic overlaps are reflected at the molecular levels and raise questions about the
validity of separating these two entities. It is hoped that as we better understand the genetic basis of these entities in relation to
ultimate patient outcome, the suggested use of the term of “Borderline Breast Disease” can minimize the number of patients
who are subject to over treatment.
Biography
Shahla Masood, M.D. is an professor in the department of Pathology and Laboratory Medicine at the University of Florida College of Medicine–Jacksonville. She
is Chair, Department of Pathology and Laboratory Medicine; Program Director, Breast Pathology Fellowship; Medical Director, Breast Health Center; Program
Director, Cytopathology Fellowship; Director of Research. Clinical Special Interests: Breast pathology, cytopathology. Research Special Interests: Early breast
cancer detection; use of minimally invasive procedures to provide optimal samples for analysis; prognostic/predictive index.
Shahla Masood
University of Florida College of Medicine – Jacksonville, USA